NIH PAR · NIDA · UG3, UH3
PAR-25-446: Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of this Funding Opportunity (NOFO) is to solicit grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including medications and medical devices to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.
- NOFO number
- PAR-25-446
- Type
- PAR
- Activity code
- UG3UH3
- Primary institute
- NIDA · National Institute on Drug Abuse
- Clinical trials
- Optional
- Posted
- Sep 10, 2025
- Opens
- Sep 20, 2025
- Expires
- Aug 22, 2028
PAR-25-446 due dates
6 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| October 20, 2025 | November 20, 2025 | December 22, 2025 | March 2026 | May 2026 | July 2026 |
| February 20, 2026 | March 20, 2026 | April 20, 2026 | July 2026 | October 2026 | December 2026 |
| June 22, 2026 | July 20, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 20, 2026 | November 20, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 22, 2027 | March 22, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 21, 2027 | July 20, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 20, 2027 | November 22, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 22, 2028 | March 20, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 20, 2028 | July 20, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
Projects funded under PAR-25-446
NIH RePORTER lists 3 projects funded under PAR-25-446 in FY2022–FY2026, with $4.1M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$4.1M
Award dollars under PAR-25-446, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $4.1M |
Institutions with the most funding
- University of Mississippi Med Ctr$1.8M · 1 project
- Flik Therapeutics, Inc.$1.6M · 1 project
- University of Alabama at Birmingham$662K · 1 project
Funding institutes
- NIDA$4.1M · 3
Activity codes funded
- UG33 records
Most recent new awards
- Development of a Novel Treatment for Benzodiazepine Addiction (opens NIH RePORTER)
University of Mississippi Med Ctr · 1UG3DA065285-01A1 · NIDA · Notice Sep 18, 2026
$1.8MUG3
- Translational Development of a Novel Therapeutic for Tobacco Dependence (opens NIH RePORTER)
Flik Therapeutics, Inc. · 1UG3DA067092-01 · NIDA · Notice Sep 7, 2026
$1.6MUG3
- Psilocybin in the treatment of methamphetamine use disorder (opens NIH RePORTER)
University of Alabama at Birmingham · 1UG3DA067126-01 · NIDA · Notice Aug 14, 2026
$662KUG3
What its predecessor PAR-25-329 funded
PAR-25-446 reissues PAR-25-329. Its funding history is the best guide to who wins under this program: 3 projects and $6.7M in FY2022–FY2026.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$6.7M
Award dollars under PAR-25-329, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $6.7M |
Institutions with the most funding
- UT Southwestern Medical Center$3.6M · 2 projects
- Newleos Therapeutics, Inc.$3.1M · 1 project
Funding institutes
- NIDA$6.7M · 3
Activity codes funded
- UG33 records
Most recent new awards
- NTX-2001, a trace amine-associated receptor 1 (TAAR1) partial agonist, for the treatment of Cocaine Use Disorder (opens NIH RePORTER)
Newleos Therapeutics, Inc. · 1UG3DA066264-01 · NIDA · Notice Sep 8, 2026
$3.1MUG3
- Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder (opens NIH RePORTER)
UT Southwestern Medical Center · 1UG3DA066252-01 · NIDA · Notice Jul 21, 2026
$2.8MUG3
- Advancing Pregnenolone as a Novel Therapy for Co-Occurring Cannabis Use Disorder and Depression (opens NIH RePORTER)
UT Southwestern Medical Center · 1UG3DA066242-01 · NIDA · Notice May 18, 2026
$825KUG3
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-446. Contact the program officer at the institute that fits your research before applying.
- NIDA · National Institute on Drug Abuse
- none
Related notices
Nov 24, 2025 · NOT-DA-25-042
Notice to Expire PAR-25-023, Device Based Treatments for Substance Use Disorders UG3/UH3 Clinical Trial Optional)". See Notice NOT-DA-25-042.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025.
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 3 million per year for direct costs.
- Project period
- The maximum period of support is 5 years. The maximum period of support for the UG3 Phase is 2 years, and the maximum period of support for the UH3 Phase is 3 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-25-329.
Other open NOFOs for UG3, UH3
- RFA-NS-27-007HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)NINDS · next due Oct 21, 2026
- PAR-24-293Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)NINDS · next due Jan 15, 2027
- PAR-25-383Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)NINDS · next due Jan 28, 2027
- PAR-27-015Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)NIDCR · next due Oct 16, 2026
- RFA-RM-27-012PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)RMOD · next due Oct 19, 2026
- RFA-RM-27-013Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)RMOD · next due Oct 19, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.